Universität zu Köln

Elbelt, Ulf ORCID: 0000-0002-7510-9284, Schlaffer, Sven M., Buchfelder, Michael, Knappe, Ulrich J., Vila, Greisa ORCID: 0000-0003-1918-1959, Micko, Alexander, Deutschbein, Timo, Unger, Nicole, Lammert, Alexander, Topuzoglu-Mueller, Tengue, Bojunga, Joerg, Droste, Michael, Johanssen, Sarah, Kolenda, Herbert, Ritzel, Katrin, Buslei, Rolf, Strasburger, Christian J., Petersenn, Stephan and Honegger, Juergen (2020). Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. J. Clin. Endocrinol. Metab., 105 (3). S. E660 - 16. WASHINGTON: ENDOCRINE SOC. ISSN 1945-7197

Full text not available from this repository.

Abstract

Context: Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging. Objective: We therefore aimed to report on clinical characteristics leading to initiation of TMZ therapy and to add evidence on TMZ long-term effectiveness. Design and subjects: Retrospective survey on TMZ treatment in patients with APTs or PCs. TMZ therapy was initiated in 47 patients (22 females) with APTs (n = 34) or PCs (n = 13). Mean age at diagnosis was 45 +/- 15 years. The immunohistochemical subtypes were corticotroph (n = 20), lactotroph (n = 18), and nonfunctioning (n = 9) tumors. TMZ therapy started 8 years after initial diagnosis using a standard regimen (median 6 cycles) for the majority of patients. Results: Long-term radiological response to TMZ after a median follow-up of 32 months with 4 patients still on TMZ therapy was tumor regression for 9 (20%), stable disease for 8 (17%), and tumor progression for 29 patients (63%) (outcome data available for 46 patients). Progression occurred 16 months after initiation of TMZ. Median estimated progression-free survival was 23 months. Disease stabilization and median progression-free survival did not differ between patients with APTs or PCs. Predictors of tumor response were not identified. Overall, TMZ was well tolerated. Conclusion: We performed a nationwide survey on TMZ therapy in patients with APTs and PCs. While early response rates to TMZ are promising, long-term outcome is less favorable. Prolonged TMZ administration should be considered. We were not able to confirm previously reported predictors of tumor response to TMZ.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Elbelt, Ulf UNSPECIFIED orcid.org/0000-0002-7510-9284 UNSPECIFIED Schlaffer, Sven M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Buchfelder, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Knappe, Ulrich J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vila, Greisa UNSPECIFIED orcid.org/0000-0003-1918-1959 UNSPECIFIED Micko, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Deutschbein, Timo UNSPECIFIED UNSPECIFIED UNSPECIFIED Unger, Nicole UNSPECIFIED UNSPECIFIED UNSPECIFIED Lammert, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Topuzoglu-Mueller, Tengue UNSPECIFIED UNSPECIFIED UNSPECIFIED Bojunga, Joerg UNSPECIFIED UNSPECIFIED UNSPECIFIED Droste, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Johanssen, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Kolenda, Herbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Ritzel, Katrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Buslei, Rolf UNSPECIFIED UNSPECIFIED UNSPECIFIED Strasburger, Christian J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Petersenn, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Honegger, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-342373
DOI:	10.1210/clinem/dgz211
Journal or Publication Title:	J. Clin. Endocrinol. Metab.
Volume:	105
Number:	3
Page Range:	S. E660 - 16
Date:	2020
Publisher:	ENDOCRINE SOC
Place of Publication:	WASHINGTON
ISSN:	1945-7197
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language EUROPEAN-SOCIETY; TUMORS; MGMT; CLASSIFICATION Multiple languages Endocrinology & Metabolism Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/34237